• HOME
  • RESEARCH
    • Biology and dysregulation of IncRNAs
    • Ribosomopathies
    • Epigenetic engineering
    • Engineering cellular immunotherapies
    • Drugging SARS-CoV2 RNA-protein interactions
    • Funding
  • PUBLICATIONS
  • WHO WE ARE
    • Principal Investigator
    • Members
    • Collaborators
    • Alumni
    • Positions Available
    • Lab News
    • Communities
  • MENTORSHIP
  • ENTREPRENEURSHIP
  • CONTACT US
Novina Lab - Engineering Biological Technologies into Therapies

Congratulations!

9/3/2018

0 Comments

 
Dr. Fred Mermelstein (Left) and Dr. Carl Novina (Right) will serve as Harvard Biotech Incubator's (HBI) Academic and Industry Advisors for the 2018-2019 academic year. HBI is a part of the Harvard Biotech Club, which focuses on teaching students and fellows the key concepts of biotechnology and drug development, through inception to commercialization. This will be Dr. Mermelstein and Dr. Novina's second year as advisors for the HBI. This year, they will be working on developing a novel drug discovery platform aimed at disrupting lncRNA-protein interactions. Read more about the incubator here.
0 Comments

    Novina Lab News

    Archives

    July 2021
    May 2021
    February 2021
    January 2021
    December 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    March 2020
    January 2020
    December 2019
    September 2019
    July 2019
    January 2019
    October 2018
    September 2018
    August 2018
    July 2018
    May 2018
    April 2018
    March 2018
    January 2018

    Categories

    All
    Funding
    Lab Updates

    RSS Feed

 HOME | RESEARCH | PUBLICATIONS | WHO WE ARE | MENTORSHIP | ENTREPRENEURSHIP | SUPPORT US | CONTACT US

©2017 Novina Lab at Dana-Farber Cancer Institute